Ariya Bio is an ETH-Zürich spin-off developing genome-engineered red cells to cure blood disorders. We utilize established CRISPR-Cas9 gene-editing technology to reprogram red blood cells to increase the production of proteins that play a key role in some of the most common genetic blood disorders worldwide. Our lead project aims at curing the Beta-Hemoglobinopathies, which are the most common monogenetic diseases worldwide, with approximately 360 000 annual births with a serious form of the disease, and 7% of the world population are disease carriers. Current treatment options are limited, and no safe curative treatments exist.
We are developing a one-time CRISPR-Cas9-based gene therapy that will reduce all disease symptoms in patients.